In a phase 2 trial of 50 treatment-seeking adults with moderate to severe alcohol use disorder, oral semaglutide did not significantly reduce lab cue-elicited craving (primary outcome) vs placebo over 8 weeks; it reduced heavy drinking days (secondary) but not drinks per day.
RCTn = 50
Schacht et al. Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial